<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003658</url>
  </required_header>
  <id_info>
    <org_study_id>98-083</org_study_id>
    <secondary_id>CDR0000066751</secondary_id>
    <secondary_id>NCI-G98-1482</secondary_id>
    <nct_id>NCT00003658</nct_id>
  </id_info>
  <brief_title>Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Other B-cell Cancers</brief_title>
  <official_title>A Phase I-II Study of Pentostatin With Cyclophosphamide for Previously Treated Patients With Intermediate and High-Risk Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die. Monoclonal antibodies, such as rituximab, can locate tumor cells
      and either kill them or deliver tumor-killing substances to them without harming normal
      cells. Combining chemotherapy with monoclonal antibody therapy may kill more cancer cells.

      PURPOSE: Phase II trial to study the effectiveness of combining pentostatin,
      cyclophosphamide, and rituximab in treating patients who have chronic lymphocytic leukemia or
      other B-cell cancers that have been treated previously.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the dose of cyclophosphamide, with filgrastim (G-CSF) support, that can be
           safely administered with pentostatin and rituximab in patients with previously treated
           intermediate- or high-risk chronic lymphocytic leukemia or other low-grade B-cell
           malignancies. (Phase I closed to accrual effective 11/27/2001.)

        -  Characterize the toxicity of this regimen in these patients.

        -  Determine the incidence of response in these patients treated with this regimen.

      OUTLINE: This is a multicenter, dose-escalation study of cyclophosphamide (CTX).

        -  Phase I: Patients receive CTX IV followed by pentostatin IV on day 1 of course 1.
           Patients also receive filgrastim (G-CSF) subcutaneously once daily beginning on day 3
           and continuing until blood counts recover. During the second and subsequent courses,
           patients receive CTX IV, pentostatin IV, and rituximab IV on day 1. Patients also
           receive G-CSF as in course 1. Treatment repeats every 3 weeks for 3 courses in the
           absence of disease progression or unacceptable toxicity. Patients with at least a
           partial response after the third course receive an additional 3 courses.

      Cohorts of 3-6 patients receive escalating doses of CTX until the maximum tolerated dose
      (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 6
      patients experience dose-limiting toxicity.

      (Phase I closed to accrual effective 11/27/2001.)

        -  Phase II: Patients receive CTX at the recommended phase II dose and treatment as above.

      Patients are followed at least every 3 months for 1 year and then periodically thereafter.

      PROJECTED ACCRUAL: A total of 3-30 patients will be accrued for the phase I portion of this
      study. (Phase I closed to accrual effective 11/27/2001.) A total of 14-30 patients will be
      accrued for the phase II portion of this study within 2.5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1998</start_date>
  <completion_date type="Actual">October 2005</completion_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pentostatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Intermediate- or high-risk chronic lymphocytic leukemia (CLL) as defined by the
             three-stage Rai system

               -  Rai intermediate disease must be active disease (including weight loss, fatigue,
                  fevers, evidence of progressive marrow failure, splenomegaly, progressive
                  lymphadenopathy, and progressive lymphocytosis with a rapid doubling time)

          -  Other low-grade B-cell neoplasms, including small lymphocytic lymphoma (and its
             variants), Waldenstrom's macroglobulinemia, and follicular lymphoma allowed

          -  Autoimmune hemolytic anemia or autoimmune thrombocytopenia allowed regardless of
             disease stage

          -  B-cells demonstrated by immunophenotypic (or immunohistochemical) analysis of the
             malignant lymphocytes

          -  Must be previously treated

          -  For CLL, absolute lymphocytosis in the blood at least 5,000 lymphocytes/mm^3 OR

          -  Bone marrow lymphocytosis at least 30% of all nucleated cells

          -  No Rai intermediate-risk disease that meets the criteria of Montserrat &quot;smoldering
             leukemia&quot; NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been
             adopted by PDQ. The terminology of &quot;indolent&quot; or &quot;aggressive&quot; lymphoma will replace
             the former terminology of &quot;low&quot;, &quot;intermediate&quot;, or &quot;high&quot; grade lymphoma. However,
             this protocol uses the former terminology.

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  Karnofsky 60-100%

        Life expectancy:

          -  More than 4 weeks

        Hematopoietic:

          -  See Disease Characteristics

        Hepatic:

          -  Bilirubin no greater than 2.0 mg/dL

        Renal:

          -  Creatinine no greater than 2.0 mg/dL

        Other:

          -  No active infections requiring systemic antibiotics

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  At least 4 weeks since prior biologic therapy

          -  Concurrent intravenous immunoglobulin allowed

          -  Concurrent epoetin alfa allowed

        Chemotherapy:

          -  At least 4 weeks since prior chemotherapy

          -  No other concurrent chemotherapy

        Endocrine therapy:

          -  Concurrent prednisone therapy allowed as long as dose is stable or decreasing over the
             past 4 weeks

          -  No increase in prednisone therapy while on study

        Radiotherapy:

          -  At least 4 weeks since prior radiotherapy

          -  No concurrent radiotherapy

        Surgery:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Adam Weiss, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lamanna N, Kalaycio M, Maslak P, Jurcic JG, Heaney M, Brentjens R, Zelenetz AD, Horgan D, Gencarelli A, Panageas KS, Scheinberg DA, Weiss MA. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol. 2006 Apr 1;24(10):1575-81. Epub 2006 Mar 6.</citation>
    <PMID>16520464</PMID>
  </results_reference>
  <results_reference>
    <citation>Weiss MA, Maslak PG, Jurcic JG, Scheinberg DA, Aliff TB, Lamanna N, Frankel SR, Kossman SE, Horgan D. Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J Clin Oncol. 2003 Apr 1;21(7):1278-84.</citation>
    <PMID>12663715</PMID>
  </results_reference>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 24, 2013</last_update_submitted>
  <last_update_submitted_qc>June 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2013</last_update_posted>
  <keyword>Waldenstr√∂m macroglobulinemia</keyword>
  <keyword>stage II chronic lymphocytic leukemia</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>B-cell chronic lymphocytic leukemia</keyword>
  <keyword>stage I grade 1 follicular lymphoma</keyword>
  <keyword>stage I grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>contiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>stage I small lymphocytic lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Pentostatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

